Karyopharm Therapeutics Inc. (KPTIQ): who owns it and who trades it
As of Nov 16, 2026, KPTIQ insiders reported 21 open-market sales worth $351K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard A. Paulson (CEO), with $137K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Karyopharm Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KPTIQ
96 funds and institutions reported KPTIQ shares worth $214M at the end of Q2 2026, about 96% of the company. The largest holder is Ra Capital Management, L.P. with 8.5%.
Funds and institutions (13F) 96%Everyone else 4%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 1.92M | 8.46% | $18.7M | No change |
| Adage Capital Partners Gp, L.l.c. | 1.52M | 6.71% | $14.9M | -16% |
| Acorn Capital Advisors, LLC | 1.52M | 6.70% | $14.8M | +427% |
| Goldman Sachs Group Inc | 1.42M | 6.29% | $13.9M | +50% |
| BlackRock, Inc. | 1.42M | 6.26% | $13.9M | +479% |
| Kalehua Capital Management LLC | 1.37M | 6.05% | $13.4M | New |
| Vanguard Capital Management LLC | 958,979 | 4.23% | $9.4M | +30% |
| Catalio Capital Management, LP | 940,855 | 4.15% | $9.2M | +5% |
| Avidity Partners Management LP | 924,487 | 4.08% | $9M | -0% |
| T. Rowe Price Investment Management, Inc. | 786,309 | 3.47% | $7.7M | -49% |
| Two Sigma Investments, LP | 695,264 | 3.07% | $6.8M | +360% |
| NEA Management Company, LLC | 576,780 | 2.55% | $5.6M | New |
| Geode Capital Management, LLC | 531,231 | 2.34% | $5.2M | +158% |
| Ghisallo Capital Management LLC | 500,000 | 2.21% | $4.9M | New |
| Soleus Capital Management, L.P. | 440,000 | 1.94% | $4.3M | No change |
| UBS Group AG | 353,545 | 1.56% | $3.5M | +82% |
| State Street Corp | 325,991 | 1.44% | $3.2M | +304% |
| Affinity Asset Advisors, LLC | 312,500 | 1.38% | $3.1M | -38% |
| Brevan Howard Capital Management LP | 309,817 | 1.37% | $3M | +46% |
| Millennium Management LLC | 305,676 | 1.35% | $3M | -27% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KPTIQ insiders reported $0 of open-market purchases and $351K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 4,788 | $0.34 | $1.6K | Form 4 |
| Oct 1, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 378 | $1.19 | $450 | Form 4 |
| Sep 1, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 19 | $2.02 | $38 | Form 4 |
| Jul 28, 2026 | Stuart Poulton | Vice president | Sale | 189 | $7.10 | $1.3K | Form 4 |
| May 14, 2026 | Stuart Poulton | Vice president | Sale | 403 | $9.50 | $3.8K | Form 4 |
| May 14, 2026 | Reshma Rangwala | Vice president | Sale | 408 | $9.50 | $3.9K | Form 4 |
| May 14, 2026 | Sohanya Roshan Cheng | Vice president | Sale | 324 | $9.50 | $3.1K | Form 4 |
| May 14, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 53 | $9.50 | $504 | Form 4 |
| May 14, 2026 | Richard A. Paulson | CEO | Sale | 2,203 | $9.50 | $20.9K | Form 4 |
| May 14, 2026 | Michael Mano | Vice president | Sale | 266 | $9.50 | $2.5K | Form 4 |
| Apr 21, 2026 | Reshma Rangwala | Vice president | Sale | 449 | $8.94 | $4K | Form 4 |
| Mar 2, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 559 | $9.41 | $5.3K | Form 4 |
| Mar 2, 2026 | Michael Mano | Vice president | Sale | 3,526 | $9.41 | $33.2K | Form 4 |
| Mar 2, 2026 | Sohanya Roshan Cheng | Vice president | Sale | 4,604 | $9.41 | $43.3K | Form 4 |
| Mar 2, 2026 | Reshma Rangwala | Vice president | Sale | 5,066 | $9.41 | $47.7K | Form 4 |
| Mar 2, 2026 | Richard A. Paulson | CEO | Sale | 12,361 | $9.41 | $116K | Form 4 |
| Mar 2, 2026 | Stuart Poulton | Vice president | Sale | 5,101 | $9.41 | $48K | Form 4 |
| Feb 17, 2026 | Stuart Poulton | Vice president | Sale | 378 | $8.63 | $3.3K | Form 4 |
| Feb 3, 2026 | Lori Macomber | CFO | Sale | 1,626 | $6.30 | $10.2K | Form 4 |
| Jan 28, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 50 | $7.03 | $352 | Form 4 |
| Jan 21, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 265 | $5.96 | $1.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Richard A. Paulson | President and CEO, Director | – | $137K | May 14, 2026 |
| Stuart Poulton | EVP, Chief Development Officer | – | $56.4K | Jul 28, 2026 |
| Reshma Rangwala | EVP & Chief Medical Officer | – | $55.6K | May 14, 2026 |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | – | $46.4K | May 14, 2026 |
| Michael Mano | EVP, CLO&Secretary | – | $35.7K | May 14, 2026 |
| Lori Macomber | EVP, CFO & Treasurer | – | $10.2K | Feb 3, 2026 |
| Kristin Abate | Chief Accounting Officer | – | $9.8K | Oct 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
Karyopharm Therapeutics company events
Karyopharm Therapeutics filed 19 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing, bankruptcy). The latest was on Nov 5, 2026.
- Nov 5, 2026ListingAs previously disclosed, on November 2, 2026, Karyopharm Therapeutics Inc. and its subsidiary, KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions under Chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of… Filing
- Nov 3, 2026BankruptcyAnd Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference. Filing
- Nov 2, 2026AnnouncementShared information with investors. Filing
- Oct 22, 2026AnnouncementAs previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026, and the applicable parties subsequently extended… Filing
- Oct 14, 2026AnnouncementMade another announcement. Filing
- Sep 18, 2026SharesChanged the rights of its shareholders. Filing
- Sep 11, 2026AgreementKaryopharm Therapeutics Inc. and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures to provide the Company with additional time to continue to advance its myelofibrosis program, further negotiate with its lenders, pursue strategic alternatives, or… Filing
- Aug 31, 2026AnnouncementKaryopharm Therapeutics Inc. announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking Accelerated Approval for XPOVIO ® (selinexor) in combination with ruxolitinib for patients with myelofibrosis. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 31, 2026AnnouncementKaryopharm Therapeutics Inc. announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer. Filing
- Jul 17, 2026LeadershipThe Board of Directors of Karyopharm Therapeutics Inc., upon recommendation of its Compensation Committee, implemented a retention program for certain employees of the Company, including each of the Company’s named executive officers and the Chief Financial Officer. Filing
- May 28, 2026LeadershipAmendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended At th e 2026 Annual Meeting of Stockholders of Karyopharm Therapeutics Inc. held on May 21, 2026, the Company’s stockholders approved an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as… Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 27, 2026AnnouncementKaryopharm Therapeutics Inc. entered into a Securities Purchase Agreement with RA Capital Management, pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares of its common stock, par value $0.0001 per share, at a purchase price of $6.785 per share and, in lieu of Common Stock… Filing
- Mar 24, 2026AgreementKaryopharm Therapeutics Inc. entered into a Securities Purchase Agreement with RA Capital Management, pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares of its common stock, par value $0.0001 per share, at a purchase price of $6.785 per share and, in lieu of Common Stock… Filing
- Mar 3, 2026AgreementKaryopharm Therapeutics Inc. entered into the Second Amendment to Credit and Guaranty Agreement with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent, which amends the Company’s Credit and Guaranty Agreement, dated May 8, 2024 (as… Filing
- Feb 19, 2026VoteReported shareholder vote results. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementBased on preliminary unaudited financial information, the Company expects to report total revenue, which includes license and royalty revenue from partners, of approximately $33 million for the quarter ended December 31, 2025 and approximately $145 million for the year ended December 31, 2025, and… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Karyopharm Therapeutics financials
Famous investors that hold KPTIQ
2 of the 50 well-known investors we track reported holding KPTIQ in their latest 13F filing. The largest position is Ken Griffin's, worth $179K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 146,782 | $179K | 0.0% | +182% |
| Israel Englander · Millennium Management | Q3 2026 | 42,888 | $52.3K | 0.0% | -86% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named KPTIQ in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 13, 2026 | Affinity Asset Advisors, LLC | 13G/A | 6.5% |
| Nov 13, 2026 | Affinity Asset Advisors, LLC | 13G/A | 6.5% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G/A | 8.9% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G/A | 8.9% |
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G/A | 0.9% |
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G/A | 0.9% |
| Oct 28, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 0.2% |
| Oct 28, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 0.2% |
| Oct 8, 2026 | ACORN BIOVENTURES, L.P. | 13G/A | 1.9% |
| Oct 8, 2026 | ACORN BIOVENTURES, L.P. | 13G/A | 1.9% |
Questions about Karyopharm Therapeutics Inc. (KPTIQ) stock
Who owns the most KPTIQ stock?
The largest reported owner of Karyopharm Therapeutics Inc. (KPTIQ) is Ra Capital Management, L.P., with 8.5% of the company. In total, 96 funds and institutions reported holding KPTIQ at the end of Q2 2026, together about 96% of the shares. See the largest owners.
Are KPTIQ insiders buying or selling?
In the last 12 months, KPTIQ insiders reported no open-market purchases and 21 sales worth $351K. The latest trade was on Oct 16, 2026. See every trade.
Which famous investors hold KPTIQ?
2 of the 50 well-known investors we track reported KPTIQ in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $179K. See all holders.
Executive pay
Karyopharm Therapeutics's chief executive was paid a total of $2.3M for the year ended Dec 31, 2025, up 12% from $2.1M the year before. In the last 12 months, Karyopharm Therapeutics's executives and directors bought no stock on the open market and sold $351K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.